Moreover, TET2/TP53 mutation was a risk factor for PTCL patient survival (HR 3.574, 95% CI 1.069 − 11.941, P = 0.039). Here, TET2 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.